Reported results
- Research and development (R&D) expenses were $67,407 thousand for the third quarter of 2026 compared to $62,931 thousand for the third quarter of 2025.
- General and administrative (G&A) expenses were $14,844 thousand for the third quarter of 2026 compared to $10,686 thousand for the third quarter of 2025.
- Net loss was $75,557 thousand, or ($0.96) per share, for the third quarter of 2026, compared to a net loss of $67,044 thousand, or ($1.01) per share, for the third quarter of 2025.
- At September 30, 2026, Celldex had 78.5 million shares outstanding.
Guidance
- Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028.
Price and volatility reaction
The stock moved +5.7% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -3.0 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 28.27 | 2026-11-05 |
| Close after release | 29.87 | 2026-11-06 |
| Realised move | +5.7% | close to close |
| 30d ATM IV change | -3.0 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
